WO2006006283A1 - Composition for nasal cavity - Google Patents

Composition for nasal cavity Download PDF

Info

Publication number
WO2006006283A1
WO2006006283A1 PCT/JP2005/006391 JP2005006391W WO2006006283A1 WO 2006006283 A1 WO2006006283 A1 WO 2006006283A1 JP 2005006391 W JP2005006391 W JP 2005006391W WO 2006006283 A1 WO2006006283 A1 WO 2006006283A1
Authority
WO
WIPO (PCT)
Prior art keywords
lavender
nasal
composition
distilled water
nasal cavity
Prior art date
Application number
PCT/JP2005/006391
Other languages
French (fr)
Japanese (ja)
Inventor
Toshihiko Tsuda
Original Assignee
Kobayashi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co., Ltd. filed Critical Kobayashi Pharmaceutical Co., Ltd.
Publication of WO2006006283A1 publication Critical patent/WO2006006283A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Definitions

  • the present invention relates to a composition for nasal cavity. More specifically, the present invention relates to a composition for nasal cavity that improves nasal discomfort such as nasal congestion, sneezing and sneezing.
  • the water-soluble fraction (steam-distilled water) obtained by steam-distilling lavender is not known for its characteristics and effective use, and the steam-distilled water is a nasal discomfort. What kind of influence it will have on you?
  • Patent Document 1 Special Table 2004-513875
  • an object of the present invention is to solve the above-described problems of the prior art. That is, this departure Ming aims to provide a composition for nasal cavity that can effectively improve nasal discomfort such as nasal congestion, sneezing, and itchiness, and has a long-lasting safety effect.
  • the present invention provides the following inventions:
  • Item 1 A nasal composition containing lavender steam distilled water.
  • Item 2 The composition for nasal cavity according to Item 1, wherein the lavender steam-distilled water is obtained from the above-ground part or whole plant power of lavender.
  • Item 3 The nasal composition according to Item 1 or 2, wherein the lavender is Okamurasaki or an improved variety thereof.
  • composition for nasal cavity of the present invention is characterized by containing lavender steam-distilled water.
  • Lavender is a plant species belonging to the family Labiatae and Lavandula, and is an authentic lavender (scientific name; Lavandula).
  • the type of lavender to be used is not particularly limited. Particularly preferred examples include various varieties such as Okamurasaki, Hanamoiwa, dark purple early bloom, and Yodei, and more preferred are Okamurasaki or improved varieties thereof, particularly those produced in Hokkaido, Japan.
  • the lavender may be a wild species or a cultivated species.
  • lavender whole plants Preferably above ground (excluding root (Whole plant) or whole plant.
  • the steam distilled water of lavender is a distilled liquid collected by steam distillation using 0.6 to 2 parts by weight, preferably 0.8 to 1 part by weight of water with respect to 1 part by weight of lavender. It is prepared by recovering the aqueous phase.
  • the method for steam distillation is not particularly limited, but a pressurized steam distillation method is preferable.
  • the composition for nasal cavity of the present invention may be lavender steam distilled water alone, but contains other components such as a pharmaceutically acceptable base material additive. It's good.
  • the blending ratio of lavender steam distilled water in the composition for nasal cavity of the present invention may be appropriately set according to the purpose of use, the degree of symptoms, the form of the composition, etc., but as an example, the composition
  • the ratio of the lavender steam distilled water is 0.01 to: LOO wt%, preferably 0.1 to L00 wt%, more preferably 1 to L00 wt% with respect to the total amount.
  • the shape of the composition for nasal cavity of the present invention is appropriately adjusted according to the usage form.
  • Examples of the shape of the composition for nasal cavity include liquid, ointment, sol and the like. Of these, liquid is preferred.
  • Other components that can be blended in the nasal composition of the present invention include, for example, ethanol, alcohol such as methanol, water, base material components such as ointment base material, and surfactant, buffer, pH Examples thereof include additives such as regulators, isotonic agents, thickeners, dyes, preservatives, preservatives, anti-inflammatory agents, antibacterial agents, vasoconstrictors, steroids and the like.
  • the nasal composition of the present invention is employed in general nasal compositions as long as the pH and osmotic pressure do not impede the effects of the present invention. Should be set as appropriate.
  • composition for nasal cavity of the present invention is not particularly limited as long as it is applied directly into the nasal cavity. Can be used.
  • the daily dose of the nasal composition of the present invention includes the shape of the composition, the concentration of lavender steam distilled water, the age and sex of the user, the shape of the composition, the method of administration, It can be set as appropriate according to the expected degree.
  • the nasal composition of the present invention is It is usually administered by spraying, applying, dripping or flowing into the nasal cavity one to several times at a suitable dose.
  • the composition for nasal cavity of the present invention has an action of suppressing the release of histamine and an effect of suppressing the growth of various bacteria in the nasal cavity. It can also be used as a composition for inhibiting histamine release or an antibacterial composition for the nasal cavity.
  • the composition for nasal cavity of the present invention is excellent in the effect of improving nasal discomfort such as nasal congestion, sneezing and itchiness.
  • the composition for nasal cavity of the present invention can remain in the nasal mucosa for a long time and is excellent in sustainability of the effect, so that discomfort can be improved over a long period of time.
  • the effect of the present invention is excellent when using steam distilled water that can obtain the above-ground part of lavender or the total plant power.
  • composition for nasal cavity of the present invention can be used as a preventive or therapeutic agent for inflammation in the nasal cavity because it stays in the nasal mucosa for a long time and can prevent the propagation of bacteria and suppress the occurrence of inflammation. It is.
  • composition for nasal cavity of the present invention releases a pleasant aroma that has a restful and sedative effect on human beings, so that a relaxing effect can be enjoyed and a good feeling of use can be obtained.
  • a pleasant aroma that has a restful and sedative effect on human beings, so that a relaxing effect can be enjoyed and a good feeling of use can be obtained.
  • such an effect can enhance the user's or user's sense of use.
  • composition for nasal cavity of the present invention uses lavender steam distilled water, which is a naturally derived component, and has extremely low irritation to nasal mucosa and high safety.
  • FIG. 1 is a diagram showing the results (chromatograph) of lavender steam distilled water obtained in Example 1 analyzed by gas chromatography.
  • FIG. 2 is a diagram showing the results (chromatograph) of lavender essential oil analyzed by gas chromatography.
  • Example 1 The lavender steam distilled water obtained in Example 1 was evaluated for irritation to the nasal mucosa by the following method.
  • Example 1 With 6 adult males (3 healthy subjects and 3 hay fever patients) as subjects, 20 g of lavender steam distilled water obtained in Example 1 was allowed to flow into the nasal cavity and then discharged. (Test Example 1). After administration, irritation was evaluated according to the following criteria.
  • Table 1 shows the obtained results.
  • Test Example 1 it was confirmed that an unpleasant stimulus was shown, but in Comparative Test Examples 1-1, 1-3, and 1-4, an unpleasant stimulus was observed. Further, the unpleasant irritation disappeared in about 15 minutes after administration in Comparative Test Example 1-1, but in Comparative Test Examples 3 and 1-4, unpleasant irritation remained even 60 minutes after administration.
  • Comparative Example 2 Irritated and irritated by hay fever patients.
  • Example 1 The lavender steam distilled water obtained in Example 1 was evaluated for the effect of improving nasal discomfort by the following method.
  • Example 2 5 adult males suffering from hay fever! Were administered by letting 20g of lavender steam-distilled water obtained in Example 1 flow into the nasal cavity and then draining it. (Test Example 2). After administration, the degree of improvement in discomfort (nasal congestion and nasal itchiness) was evaluated according to the following criteria. The evaluation was performed immediately after administration, 5 minutes, 10 minutes, 30 minutes, 1, 2, 4 and 12 hours. In addition, the ability to reduce stress (irritability), which also causes nasal discomfort, was evaluated according to the following criteria. The evaluation was performed immediately after administration, 2 and 4 hours later.
  • each numerical value shows the average value of the score.
  • a lavender essential oil-containing solution (1% by weight of lavender essential oil, 5% by weight of surfactant, remaining water) (comparative test example 3) (Comparative Test Example 3) was used instead of lavender steam distilled water, and as a control, lavender was used.
  • the test was conducted in the same manner as described above using physiological saline (manufactured by Otsuka Pharmaceutical Co., Ltd.) (control) instead of the steam distilled water. From the following formula, the inhibition rate of histamine release was calculated.
  • Test Example 4 Antibacterial evaluation test About 1 X 10 6 cells / mL of Escherichia coli ATCC 8739, Staphylococcus aureus ATCC 6538 or Pseudomonas aeruginosa ATCC 9027 in the steam distilled water of lavender obtained in Example 1 I added it to become. After the addition of the bacteria, the mixture was thoroughly stirred, and then allowed to stand at 37 ° C. After 12 hours, sampling was performed to measure the concentration of the bacteria in the liquid. The concentration of the bacteria was measured by culturing at 37 ° C for 18 hours using a blood agar plate for DD bacteria and general bacteria. For comparison, a test was performed in the same manner as described above, using physiological saline (manufactured by Otsuka Pharmaceutical Co., Ltd.) (Comparative Test Example 4) instead of Lavender's steam distilled water.
  • physiological saline manufactured by Otsuka Pharmaceutical Co., Ltd.
  • Table 5 shows the obtained results. As a result, it was confirmed that lavender steam distilled water has an excellent antibacterial action.
  • Example 1 Three subjects with hay fever with nasal discomfort were selected as subjects. Three subjects were administered by allowing 20 g of the lavender steam distilled water obtained in Example 1 to flow into the nasal cavity and then draining it. After administration, subjects were immediately put to bed and evaluated how lavender steam-distilled water had an effect on sleep! // (Study Example 5). The evaluation was performed according to the following evaluation criteria for (1) falling asleep, (2) depth of sleep, (3) awakening during sleep, and (4) awakening.
  • Table 6 shows the obtained results. As a result, it was confirmed that the composition for nasal cavity of the present invention has an excellent sleep inducing effect. From this result, since the composition for nasal cavity of the present invention can stay in the nasal cavity for a long time, it improves nasal discomfort during sleep, and furthermore, the problem of sleeping due to the fragrance component of the present invention. It was suggested that
  • the lavender steam distilled water and lavender essential oil obtained in Example 1 were subjected to component analysis by gas chromatography.
  • the lavender essential oil to be analyzed the oil phase in which the distillate power produced by steam distillation was recovered in Example 1 was used.
  • 47.5 g of lavender steam distilled water obtained in Example 1 was mixed with 2.5 g of hexane, and the lavender essential oil diluted to 1% by weight with methanol was used as samples. .
  • the analysis conditions are as follows.
  • FID hydrogen flame ionization
  • Figure 1 shows the chromatograph obtained for lavender steam distilled water
  • Figure 2 shows the chromatograph obtained for Lavender mono essential oil. The peak patterns are different between Fig. 1 and Fig. 2, and it was confirmed that the composition of lavender steam distilled water and lavender essential oil differ.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

[PROBLEMS] To provide a composition for the nasal cavity which can effectively mitigate unpleasant nasal symptoms such as nasal occlusion, sneezing, and itching, is highly safe, and has a lasting effect. [MEANS FOR SOLVING PROBLEMS] A distilled water obtained by the steam distillation of lavender is used to prepare a composition for the nasal cavity.

Description

明 細 書  Specification
鼻腔用組成物  Nasal composition
技術分野  Technical field
[0001] 本発明は鼻腔用組成物に関する。より詳細には、本発明は、鼻づまり、くしゃみ、痒 み等の鼻の不快症状を改善する鼻腔用組成物に関する。  [0001] The present invention relates to a composition for nasal cavity. More specifically, the present invention relates to a composition for nasal cavity that improves nasal discomfort such as nasal congestion, sneezing and sneezing.
背景技術  Background art
[0002] 細菌やウィルス、花粉等のアレルゲンが鼻腔粘膜に付着すると、粘膜組織からヒス タミン等の化学物質が遊離し、鼻腔粘膜の血流量が劇的に増加する。これによつて、 鼻腔粘膜は、鬱血し腫れ、多量の粘液が分泌され、鼻腔を狭めたり、詰まらせたりす る。この結果、鼻づまり、くしゃみ、痒み等の鼻の不快症状が引き起こされる。  [0002] When allergens such as bacteria, viruses and pollen adhere to the nasal mucosa, chemical substances such as histamine are released from the mucosal tissue, and the blood flow in the nasal mucosa increases dramatically. This causes the nasal mucosa to become congested and swollen, and a large amount of mucus is secreted, narrowing and clogging the nasal cavity. This results in nasal discomfort such as stuffy nose, sneezing and itching.
[0003] これまでに、鼻の不快症状を改善する手段として、抗炎症薬ゃ抗ヒスタミン薬等の 種々の薬剤の使用が提案されている。しかし、これら従来の薬剤では、安全性、効果[0003] To date, the use of various drugs such as anti-inflammatory drugs and antihistamines has been proposed as means for improving nasal discomfort. However, these conventional drugs are safe and effective.
、持続性及び使用感の全ての点を充足しているものはなぐ使用者又は施用者の要 求を満足できて 、な 、のが現状である。 However, what satisfies all the points of sustainability and feeling of use can satisfy the demands of users and users, and it is the current situation.
[0004] 従来、ラベンダー等の植物由来の精油成分には、アレルギー等による鼻の不快症 状を改善する作用があることが分力つており、この精油の作用を利用した方法として、 揮散させた該精油成分を鼻腔内に吸引させることにより鼻の不快感を改善する方法 が提案されている (例えば、特許文献 1参照)。しかしながら、このような方法では、精 油成分を揮散状態で使用するため、充分な不快感改善効果が得られないだけでなく 、効果の発現に時間がかかり、即効性の面でも欠点がある。  [0004] Conventionally, plant-derived essential oil components such as lavender have been found to have the effect of improving nasal discomfort due to allergies, etc., and have been volatilized as a method using the action of this essential oil. A method of improving nasal discomfort by aspirating the essential oil component into the nasal cavity has been proposed (see, for example, Patent Document 1). However, in such a method, since the essential oil component is used in a volatilized state, not only a sufficient discomfort improvement effect cannot be obtained, but it also takes time to manifest the effect and has a drawback in terms of immediate effect.
[0005] ところで、ラベンダーを水蒸気蒸留して得られる水溶性画分 (水蒸気蒸留水)は、そ の特性や有効な利用法については知られておらず、該水蒸気蒸留水が鼻の不快症 状に如何なる影響を及ぼすかにつ 、ては、全く分力つて 、な 、。  [0005] By the way, the water-soluble fraction (steam-distilled water) obtained by steam-distilling lavender is not known for its characteristics and effective use, and the steam-distilled water is a nasal discomfort. What kind of influence it will have on you?
特許文献 1:特表 2004— 513875号公報  Patent Document 1: Special Table 2004-513875
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0006] そこで、本発明の目的は、上記従来技術の課題を解決することである。即ち、本発 明は、鼻づまり、くしゃみ、痒み等の鼻の不快症状を効果的に改善でき、安全性が高 ぐ効果の持続性がある鼻腔用組成物を提供することを目的とする。 [0006] Accordingly, an object of the present invention is to solve the above-described problems of the prior art. That is, this departure Ming aims to provide a composition for nasal cavity that can effectively improve nasal discomfort such as nasal congestion, sneezing, and itchiness, and has a long-lasting safety effect.
課題を解決するための手段  Means for solving the problem
[0007] 本発明者らは、上記課題を解決すべく鋭意検討したところ、ラベンダーを水蒸気蒸 留することにより得られる水蒸気蒸留水には、ヒスタミンの遊離を抑制する作用がある こと、鼻づまり、くしゃみ、痒み等の鼻の不快症状を効果的に改善できること、及び該 不快症状改善効果に持続性があることを見出した。本発明は、力かる知見に基づい て、更に検討を重ねて開発されたものである。  [0007] The present inventors diligently studied to solve the above problems, and as a result, steam distilled water obtained by steam distillation of lavender has an action of suppressing histamine release, nasal congestion, It has been found that nasal discomfort such as sneezing and itchiness can be effectively improved, and that the discomfort improvement effect is persistent. The present invention has been developed based on further research and further studies.
[0008] 即ち、本発明は、下記に掲げる発明を提供するものである:  That is, the present invention provides the following inventions:
項 1. ラベンダーの水蒸気蒸留水を含有する、鼻腔用組成物。  Item 1. A nasal composition containing lavender steam distilled water.
項 2. ラベンダーの水蒸気蒸留水が、ラベンダーの地上部又は全草力 得られるも のである、項 1に記載の鼻腔用組成物。  Item 2. The composition for nasal cavity according to Item 1, wherein the lavender steam-distilled water is obtained from the above-ground part or whole plant power of lavender.
項 3. ラベンダーが、おかむらさき又はその改良品種である、項 1又は 2に記載の鼻 腔用組成物。  Item 3. The nasal composition according to Item 1 or 2, wherein the lavender is Okamurasaki or an improved variety thereof.
[0009] 以下に、本発明を詳細に説明する。本発明の鼻腔用組成物は、ラベンダーの水蒸 気蒸留水を含有することを特徴とするものである。  [0009] The present invention is described in detail below. The composition for nasal cavity of the present invention is characterized by containing lavender steam-distilled water.
[0010] ラベンダーは、シソ科 (Labiatae)、ラバンジュラ属 (Lavandula)に属する植物種であ り、真正ラベンダー(学名; Lavandula [0010] Lavender is a plant species belonging to the family Labiatae and Lavandula, and is an authentic lavender (scientific name; Lavandula).
angustifoliaゝ異学名; L. officinalis^し vera)、スノ《イクラベンター (学名; L.spica、異学 名; L.latifolia)、ストェカス(学名; L.stoechas)、ラバンジン(学名; L.hybrida)などが挙 げられる。本発明において、使用するラベンダーの種については特に制限されない 力 好ましいものとして真正ラベンダーを挙げることができる。特に好ましいものとして 、おかむらさき、はなもいわ、濃紫早咲、ようていの各品種を挙げることができ、もっと も好ましくはおかむらさき又はその改良品種、特に日本の北海道産のものである。な お、ラベンダーは野生種であってもよぐ栽培種であってもよい。  L. officinalis ^ vera), Sno 《Icraventer (scientific name; L.spica), Stokes (scientific name; L.stoechas), Labandin (scientific name; L.hybrida) And so on. In the present invention, the type of lavender to be used is not particularly limited. Particularly preferred examples include various varieties such as Okamurasaki, Hanamoiwa, dark purple early bloom, and Yodei, and more preferred are Okamurasaki or improved varieties thereof, particularly those produced in Hokkaido, Japan. The lavender may be a wild species or a cultivated species.
[0011] ラベンダーの水蒸気蒸留水の原料としては、ラベンダーの花、花穂、果実、果皮、 茎、葉、枝、枝葉、幹、榭皮、根茎、根皮、種子をいずれか単独で、又は組み合わせ て使用してもよぐまたラベンダーの全草を使用してもよい。好ましくは地上部 (根を除 く全草)又は全草である。 [0011] As a raw material of lavender steam-distilled water, lavender flowers, spikes, fruits, pericarp, stems, leaves, branches, branches and leaves, stems, crusts, rhizomes, root barks, seeds, either alone or in combination You can also use lavender whole plants. Preferably above ground (excluding root (Whole plant) or whole plant.
[0012] ラベンダーの水蒸気蒸留水は、ラベンダー 1重量部に対して、水 0. 6〜2重量部、 好ましくは 0. 8〜1重量部を用いて、水蒸気蒸留を行い、捕集した蒸留液の水相を 回収することにより調製される。水蒸気蒸留の方法については特に制限されないが、 好ましくは加圧水蒸気蒸留法が挙げられる。  [0012] The steam distilled water of lavender is a distilled liquid collected by steam distillation using 0.6 to 2 parts by weight, preferably 0.8 to 1 part by weight of water with respect to 1 part by weight of lavender. It is prepared by recovering the aqueous phase. The method for steam distillation is not particularly limited, but a pressurized steam distillation method is preferable.
[0013] 本発明の鼻腔用組成物は、ラベンダーの水蒸気蒸留水単独力 なるものであって もよいが、薬学的に許容される基材ゃ添加剤等の他の成分を含むものであってもよ い。本発明の鼻腔用組成物中のラベンダーの水蒸気蒸留水の配合割合については 、使用目的、症状の程度、組成物の形態等に応じて適宜設定すればよいが、一例と して、該組成物の総量に対してラベンダーの水蒸気蒸留水が 0. 01〜: LOO重量%、 好ましくは 0. 1〜: L00重量%、更に好ましくは 1〜: L00重量%となる割合が挙げられ る。  [0013] The composition for nasal cavity of the present invention may be lavender steam distilled water alone, but contains other components such as a pharmaceutically acceptable base material additive. It's good. The blending ratio of lavender steam distilled water in the composition for nasal cavity of the present invention may be appropriately set according to the purpose of use, the degree of symptoms, the form of the composition, etc., but as an example, the composition The ratio of the lavender steam distilled water is 0.01 to: LOO wt%, preferably 0.1 to L00 wt%, more preferably 1 to L00 wt% with respect to the total amount.
[0014] 本発明の鼻腔用組成物の形状については、使用形態に応じて適宜調整される。鼻 腔用組成物の形状の一例として、液状、軟膏状、ゾル状等が挙げられる。これらの中 で、好ましくは液状である。  [0014] The shape of the composition for nasal cavity of the present invention is appropriately adjusted according to the usage form. Examples of the shape of the composition for nasal cavity include liquid, ointment, sol and the like. Of these, liquid is preferred.
[0015] 本発明の鼻腔用組成物に配合可能な他の成分として、例えば、エタノール、メタノ ール等のアルコール、水、軟膏基材等の基材成分;及び界面活性剤、緩衝剤、 pH 調整剤、等張化剤、増粘剤、色素、保存剤、防腐剤、抗炎症剤、抗菌剤、血管収縮 剤、ステロイド剤等の添加剤を挙げることができる。  [0015] Other components that can be blended in the nasal composition of the present invention include, for example, ethanol, alcohol such as methanol, water, base material components such as ointment base material, and surfactant, buffer, pH Examples thereof include additives such as regulators, isotonic agents, thickeners, dyes, preservatives, preservatives, anti-inflammatory agents, antibacterial agents, vasoconstrictors, steroids and the like.
[0016] 本発明の鼻腔用組成物は、 pHや浸透圧については、本発明の効果を妨げないこ とを限度として、一般の鼻腔用組成物に採用されて 、る pH及び浸透圧の範囲内に 適宜設定すればよい。  [0016] The nasal composition of the present invention is employed in general nasal compositions as long as the pH and osmotic pressure do not impede the effects of the present invention. Should be set as appropriate.
[0017] 本発明の鼻腔用組成物は、鼻腔内に直接適用されるものである限り、その用途に ついては特に制限されなが、例えば医薬用又は一般用の洗鼻剤や点鼻剤として使 用することができる。  [0017] The use of the composition for nasal cavity of the present invention is not particularly limited as long as it is applied directly into the nasal cavity. Can be used.
[0018] 本発明の鼻腔用組成物の一日当たりの投与量としては、該組成物の形状、ラベン ダ一の水蒸気蒸留水の濃度、使用者の年齢や性別、組成物の形状、投与方法、期 待される程度等に応じて適宜設定することができる。本発明の鼻腔用組成物は、通 常、 1回当たり適量を 1回乃至数回、鼻腔内に噴霧、塗布、滴下又は流入させること により投与される。 [0018] The daily dose of the nasal composition of the present invention includes the shape of the composition, the concentration of lavender steam distilled water, the age and sex of the user, the shape of the composition, the method of administration, It can be set as appropriate according to the expected degree. The nasal composition of the present invention is It is usually administered by spraying, applying, dripping or flowing into the nasal cavity one to several times at a suitable dose.
[0019] なお、以下の試験例に示すように、本発明の鼻腔用組成物には、ヒスタミンの遊離 を抑制する作用や鼻腔内の雑菌の繁殖を抑制する作用が認められるので、鼻腔用 のヒスタミン遊離抑制用組成物又は鼻腔用の抗菌用組成物として使用することもでき る。  [0019] As shown in the following test examples, the composition for nasal cavity of the present invention has an action of suppressing the release of histamine and an effect of suppressing the growth of various bacteria in the nasal cavity. It can also be used as a composition for inhibiting histamine release or an antibacterial composition for the nasal cavity.
発明の効果  The invention's effect
[0020] 本発明の鼻腔用組成物は、鼻づまり、くしゃみ、痒み等の鼻の不快症状を改善する 効果に優れている。また、本発明の鼻腔用組成物は、鼻腔粘膜に長時間留まること ができ、効果の持続性に優れているので、不快症状を長期にわたって改善すること ができる。特に、上記本発明の効果は、ラベンダーの地上部又は全草力も得られる 水蒸気蒸留水を使用する場合に優れている。  [0020] The composition for nasal cavity of the present invention is excellent in the effect of improving nasal discomfort such as nasal congestion, sneezing and itchiness. In addition, the composition for nasal cavity of the present invention can remain in the nasal mucosa for a long time and is excellent in sustainability of the effect, so that discomfort can be improved over a long period of time. In particular, the effect of the present invention is excellent when using steam distilled water that can obtain the above-ground part of lavender or the total plant power.
[0021] また、本発明の鼻腔用組成物は、鼻腔粘膜に長時間留まることにより、雑菌の繁殖 を防いで炎症の発生を抑制できるので、鼻腔内の炎症の予防又は治療剤としても有 用である。  In addition, the composition for nasal cavity of the present invention can be used as a preventive or therapeutic agent for inflammation in the nasal cavity because it stays in the nasal mucosa for a long time and can prevent the propagation of bacteria and suppress the occurrence of inflammation. It is.
[0022] 更に、本発明の鼻腔用組成物は、人間に対する安眠効果や鎮静効果を奏する心 地よい芳香を放出させるので、リラックス効果を享受でき、良好な使用感を得ることが できる。また、このような効果が奏されることによって、使用者や施用者の使用実感を 高めることができる。  [0022] Furthermore, the composition for nasal cavity of the present invention releases a pleasant aroma that has a restful and sedative effect on human beings, so that a relaxing effect can be enjoyed and a good feeling of use can be obtained. In addition, such an effect can enhance the user's or user's sense of use.
[0023] また、本発明の鼻腔用組成物は、天然由来成分であるラベンダーの水蒸気蒸留水 を使用しており、鼻粘膜に対する刺激性が極めて低ぐ安全性が高い。  [0023] The composition for nasal cavity of the present invention uses lavender steam distilled water, which is a naturally derived component, and has extremely low irritation to nasal mucosa and high safety.
図面の簡単な説明  Brief Description of Drawings
[0024] [図 1]実施例 1で得られたラベンダーの水蒸気蒸留水をガスクロマトグラフィーにより 分析した結果 (クロマトグラフ)を示す図である。  FIG. 1 is a diagram showing the results (chromatograph) of lavender steam distilled water obtained in Example 1 analyzed by gas chromatography.
[図 2]ラベンダー精油をガスクロマトグラフィーにより分析した結果 (クロマトグラフ)を示 す図である。  FIG. 2 is a diagram showing the results (chromatograph) of lavender essential oil analyzed by gas chromatography.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0025] 以下、実施例及び試験例を挙げて本発明を説明するが、本発明はこれらの実施例 に限定されるものではない。 Hereinafter, the present invention will be described with reference to examples and test examples. However, the present invention is not limited to these examples. It is not limited to.
実施例 1  Example 1
ラベンダー(おかむらさき)の地上部 (根を除く全草) 60kgに対して、水約 50kgを用 いて加圧水蒸気蒸留を行い、水相 36kg及び油相 0. 36kgを含む蒸留液を製した。 蒸留液から水相を回収して、ラベンダーの水蒸気蒸留水を得た。  About 60 kg of lavender (Okamurasaki) above ground (whole plant excluding roots) was subjected to pressurized steam distillation using about 50 kg of water to produce a distillate containing 36 kg of water phase and 0.36 kg of oil phase. The aqueous phase was recovered from the distillate to obtain lavender steam distilled water.
[0026] 試験例 1 刺激性評価  [0026] Test Example 1 Evaluation of irritation
実施例 1で得られたラベンダーの水蒸気蒸留水について、以下の方法により鼻腔 粘膜に対する刺激性の評価試験を行なった。  The lavender steam distilled water obtained in Example 1 was evaluated for irritation to the nasal mucosa by the following method.
[0027] 成人男性 6名(健常者 3名と花粉症患者 3名)を被験者として、実施例 1で得られた ラベンダーの水蒸気蒸留水 20gを鼻腔内に流入させた後これを排出することによつ て投与した (試験例 1)。投与後、下記基準に従って、刺激性について評価した。また 、比較として、ラベンダーの水蒸気蒸留水の代わりに、精製水 (大塚製薬株式会社製 ) (比較試験例 1-1);生理食塩水 (大塚製薬株式会社製)(比較試験例 1-2);ラベン ダー精油含有溶液 (ラベンダー精油 1重量%、界面活性剤 5重量%、残部水)(比較 試験例 1-3);又はラベンダー精油含有溶液 (ラベンダー精油 1重量%、界面活性剤 5 重量%、食塩 0. 9重量%、残部水)(比較試験例 1-4)を用いて、上記と同様に試験 を行った。  [0027] With 6 adult males (3 healthy subjects and 3 hay fever patients) as subjects, 20 g of lavender steam distilled water obtained in Example 1 was allowed to flow into the nasal cavity and then discharged. (Test Example 1). After administration, irritation was evaluated according to the following criteria. For comparison, purified water (manufactured by Otsuka Pharmaceutical Co., Ltd.) (Comparative Test Example 1-1) instead of lavender steam distilled water; physiological saline (manufactured by Otsuka Pharmaceutical Co., Ltd.) (Comparative Test Example 1-2) Lavender essential oil-containing solution (lavender essential oil 1% by weight, surfactant 5% by weight, balance water) (Comparative Test Example 1-3); or lavender essential oil-containing solution (lavender essential oil 1% by weight, surfactant 5% by weight) The test was conducted in the same manner as described above using Comparative Example 1-4).
<刺激性の評価基準 >  <Irritation criteria>
(評点)  (Score)
0 :不快な刺激なし  0: No unpleasant irritation
1:どちらかと 、うと不快な刺激なし  1: Somehow, there is no unpleasant irritation
2 :どちらともいえない  2: I can say neither
3:どちらかというと不快な刺激あり  3: Somewhat unpleasant stimulus
4 :不快な刺激あり。  4: Uncomfortable irritation.
[0028] 得られた結果を表 1に示す。試験例 1では、不快な刺激を示して 、な 、ことが確認 されたが、比較試験例 1-1、 1-3及び 1-4では不快な刺激が認められた。更に、不快 な刺激は、比較試験例 1-1では投与後 15分程度で治まったが、比較試験例ト 3及び 1-4では、投与から 60分間経過しても不快な刺激が残った。一方、比較試験例ト 2で は、花粉症患者にぉレ、て刺激が認められた。 [0028] Table 1 shows the obtained results. In Test Example 1, it was confirmed that an unpleasant stimulus was shown, but in Comparative Test Examples 1-1, 1-3, and 1-4, an unpleasant stimulus was observed. Further, the unpleasant irritation disappeared in about 15 minutes after administration in Comparative Test Example 1-1, but in Comparative Test Examples 3 and 1-4, unpleasant irritation remained even 60 minutes after administration. On the other hand, in Comparative Example 2 Irritated and irritated by hay fever patients.
[0029] [表 1]  [0029] [Table 1]
Figure imgf000007_0001
Figure imgf000007_0001
表中、 各数値は評点の平均値を示す。 試験例 2 鼻の不快症状改善効果の評価試験  In the table, each numerical value shows the average value of the score. Test Example 2 Evaluation test of nasal discomfort improvement effect
実施例 1で得られたラベンダーの水蒸気蒸留水について、以下の方法により鼻の 不快症状改善効果の評価を行なった。  The lavender steam distilled water obtained in Example 1 was evaluated for the effect of improving nasal discomfort by the following method.
[0030] 花粉症を患って!/、る成人男性 5人を被験者として、実施例 1で得られたラベンダー の水蒸気蒸留水 20gを鼻腔内に流入させた後これを排出させることによって投与し た (試験例 2)。投与後、不快症状 (鼻ずまり、鼻のむず痒さ)の改善の程度を下記基 準に従って評価した。該評価は、投与直後、 5分後、 10分後、 30分後、 1、 2、 4及び 12時間後に行なった。更に、鼻の不快症状力も起こるストレス (イライラ感)が軽減さ れた力どうかについても、下記基準に従って評価した。該評価は、投与直後、 2及び 4時間後に行なった。また、比較として、ラベンダーの水蒸気蒸留水の代わりに、生 理食塩水 (大塚製薬株式会社製)(比較試験例 2-1)又はラベンダー精油含有溶液( ラベンダー精油 1重量%、界面活性剤 5重量%、残部水)(比較試験例 2-2)を用いて 、上記と同様に試験を行った。 [0030] 5 adult males suffering from hay fever! Were administered by letting 20g of lavender steam-distilled water obtained in Example 1 flow into the nasal cavity and then draining it. (Test Example 2). After administration, the degree of improvement in discomfort (nasal congestion and nasal itchiness) was evaluated according to the following criteria. The evaluation was performed immediately after administration, 5 minutes, 10 minutes, 30 minutes, 1, 2, 4 and 12 hours. In addition, the ability to reduce stress (irritability), which also causes nasal discomfort, was evaluated according to the following criteria. The evaluation was performed immediately after administration, 2 and 4 hours later. For comparison, instead of lavender steam distilled water, physiological saline (manufactured by Otsuka Pharmaceutical Co., Ltd.) (Comparative Test Example 2-1) or lavender essential oil-containing solution (lavender essential oil 1% by weight, surfactant 5% by weight) %, Remaining water) (Comparative Test Example 2-2).
<刺激性の評価基準 >  <Irritation criteria>
(評点)  (Score)
4:改善した  4: Improved
3 :どちらかというと改善した  3: Improved rather
2:どちらともいえない  2: I can say neither
1:どちらかと!/、うと改善して ヽな ヽ  1: Somehow!
0:改善していない  0: Not improved
1 :やや悪化した —2 :悪化した 1: Slightly worse —2: Deteriorated
<ストレス軽減効果の評価基準 >  <Evaluation criteria for stress reduction effect>
(評点)  (Score)
2 :ストレスが軽減した  2: Reduced stress
1:どちらかというとストレスが軽減した  1: Rather, stress was reduced
0 :どちらともいえない  0: Neither
- 1:どちらかとレ、うとストレスが増加した  -1: Somehow, the stress increased.
2 :ストレスが増加した。  2: Stress increased.
[0031] 得られた結果を表 2及び 3に示す。表 2から分力 ように、試験例 2では、投与直後 力 鼻の不快症状の改善効果が認められた。一方、比較試験例 2-1及び 2-2では、 不快症状の改善効果は認められな力 た。特に、比較試験例 2-2では、ラベンダー 精油による刺激が強ぐ鼻の不快症状の改善には逆効果であることが確認された。ま た、表 3から明らかなように、鼻の不快症状の改善に伴って、ストレス (イライラ感)も軽 減されることも確認された。 [0031] The results obtained are shown in Tables 2 and 3. As shown in Table 2, in Test Example 2, the effect of improving nasal discomfort immediately after administration was observed in Test Example 2. On the other hand, in Comparative Test Examples 2-1 and 2-2, the effect of improving discomfort was not recognized. In particular, Comparative Test Example 2-2 was confirmed to have an adverse effect on improving nasal discomfort, which is strongly stimulated by lavender essential oil. In addition, as is clear from Table 3, it was confirmed that stress (irritability) was reduced with improvement of nasal discomfort.
[0032] [表 2] [0032] [Table 2]
Figure imgf000008_0001
Figure imgf000008_0001
表中、 各数値は評点の平均値を示す。  In the table, each numerical value shows the average value of the score.
[0033] [表 3] [0033] [Table 3]
Figure imgf000008_0002
Figure imgf000008_0002
表中、 各数値は評点の平均値を示す。 試験例 3 ヒスタミン遊離抑制の確認試験 In the table, each numerical value shows the average value of the score. Test Example 3 Confirmation test of histamine release inhibition
本試験ではラットの肥満細胞からヒスタミン遊離試薬である compound48/80でヒスタ ミンを遊離させる試験法(J.So Cosmet.Japan, Vol.25, No.4, P246 (1992) )を用いて 、実施例 1で得られたラベンダーの水蒸気蒸留水のヒスタミン遊離抑制効果を評価し た。  This test was conducted using a test method (J. So Cosmet. Japan, Vol. 25, No. 4, P246 (1992)) that releases compound histamine from rat mast cells using compound 48/80, a histamine release reagent. The histamine release inhibitory effect of lavender steam distilled water obtained in Example 1 was evaluated.
[0034] ラット (Slc :Wister系雄性ラット,約 4〜9週齢)の腹腔内から採取した肥満細胞浮遊 液 1.2mLに、実施例 1で得られたラベンダーの水蒸気蒸留水 0.2mLと共に、 compound48/80を最終濃度 1.0 / g/mLとなるように加え、 37°Cで 15分間インキュベー トした。次いで、氷冷して反応停止させた後、反応液を遠心分離し、上澄から遊離し たヒスタミン量を、常法に従って抽出'精製し、 0-フタルジアルデヒドにて発色させ、励 起波長 360nm、蛍光波長 450nmにおける蛍光強度を測定することにより測定した。比 較として、ラベンダーの水蒸気蒸留水の代わりにラベンダー精油含有溶液 (ラベンダ 一精油 1重量%、界面活性剤 5重量%、残部水)(比較試験例 3)を用いて、またコン トロールとして、ラベンダーの水蒸気蒸留水の代わりに生理食塩水(大塚製薬株式会 社製)(コントロール)を用いて、上記と同様に試験を行った。下式から、ヒスタミン遊離 抑制率を算出した。  [0034] 1.2 mL of mast cell suspension collected from the abdominal cavity of rats (Slc: Wister male rats, about 4 to 9 weeks old) together with 0.2 mL of the lavender steam distilled water obtained in Example 1, compound48 / 80 was added to a final concentration of 1.0 / g / mL and incubated at 37 ° C for 15 minutes. Next, the reaction was stopped by cooling with ice, and then the reaction solution was centrifuged. The amount of histamine released from the supernatant was extracted and purified according to a conventional method, colored with 0-phthaldialdehyde, and the excitation wavelength. Measurement was performed by measuring fluorescence intensity at 360 nm and a fluorescence wavelength of 450 nm. For comparison, a lavender essential oil-containing solution (1% by weight of lavender essential oil, 5% by weight of surfactant, remaining water) (comparative test example 3) (Comparative Test Example 3) was used instead of lavender steam distilled water, and as a control, lavender was used. The test was conducted in the same manner as described above using physiological saline (manufactured by Otsuka Pharmaceutical Co., Ltd.) (control) instead of the steam distilled water. From the following formula, the inhibition rate of histamine release was calculated.
[0035] [数 1] ヒスタミン遊離抑制率 (%) = { 1 - (A - C) / ( B - C ) } X 1 0 0 A:試験例 3又は比較試験例 3で得られた蛍光強度の測定値  [0035] [Equation 1] Histamine release inhibition rate (%) = {1-(A-C) / (B-C)} X 1 0 0 A: Fluorescence intensity obtained in Test Example 3 or Comparative Test Example 3 Measured value of
B :コントロールの蛍光強度の測定値  B: Measured fluorescence intensity of control
C:盲検値 得られた結果を表 4に示す。この結果から、実施例 1で得られたラベンダーの水蒸 気蒸留水には、優れたヒスタミン遊離抑制作用があることが確認された。  C: Blind value Table 4 shows the results obtained. From this result, it was confirmed that the steam-distilled water of lavender obtained in Example 1 has an excellent inhibitory effect on histamine release.
[0036] [表 4] [0036] [Table 4]
Figure imgf000009_0001
試験例 4 抗菌性の評価試験 実施例 1で得られたラベンダーの水蒸気蒸留水中に、大腸菌(Escherichia coli ATCC 8739)、黄色ブドウ球菌(Staphylococcus aureus ATCC 6538)又は緑膿菌 (Pseudomonas aeruginosa ATCC 9027)を 1 X 106個/ mL程度になるように添カロ した。菌添加後よく攪拌し、その後 37°Cで静置し、 12時間後にサンプリングを行って 液中の菌濃度を測定した。菌の濃度測定は、 DDチ ッカ一一般細菌用血液寒天平 板を用いて、 37°Cで 18時間培養することにより行った。また、比較のため、ラベンダ 一の水蒸気蒸留水の代わりに、生理食塩水 (大塚製薬株式会社製)(比較試験例 4) を用いて、上記と同様に試験を行った。
Figure imgf000009_0001
Test Example 4 Antibacterial evaluation test About 1 X 10 6 cells / mL of Escherichia coli ATCC 8739, Staphylococcus aureus ATCC 6538 or Pseudomonas aeruginosa ATCC 9027 in the steam distilled water of lavender obtained in Example 1 I added it to become. After the addition of the bacteria, the mixture was thoroughly stirred, and then allowed to stand at 37 ° C. After 12 hours, sampling was performed to measure the concentration of the bacteria in the liquid. The concentration of the bacteria was measured by culturing at 37 ° C for 18 hours using a blood agar plate for DD bacteria and general bacteria. For comparison, a test was performed in the same manner as described above, using physiological saline (manufactured by Otsuka Pharmaceutical Co., Ltd.) (Comparative Test Example 4) instead of Lavender's steam distilled water.
[0037] 得られた結果を表 5に示す。この結果、ラベンダー水蒸気蒸留水には、優れた抗菌 作用があることが確認された。  [0037] Table 5 shows the obtained results. As a result, it was confirmed that lavender steam distilled water has an excellent antibacterial action.
[0038] [表 5]
Figure imgf000010_0001
試験例 5 鎮静効果 (安眠誘発効果)の評価試験
[0038] [Table 5]
Figure imgf000010_0001
Test Example 5 Evaluation test of sedation effect
鼻の不快症状のある花粉症患者 3人を被験者に選択した。被験者 3人に、実施例 1 で得られたラベンダーの水蒸気蒸留水 20gを鼻腔内に流入させた後これを排出させ ることによって投与した。投与後、被験者を直ちに就寝させ、ラベンダーの水蒸気蒸 留水が睡眠に如何なる影響を及ぼして!/、るかにつ!、て評価した (試験例 5)。なお、 評価は、(1)寝付き、(2)眠りの深さ、(3)睡眠中の目覚め、及び (4)目ざめの状態に ついて、下記評価基準に従って評価した。また、比較として、ラベンダーの水蒸気蒸 留水の代わりに、生理食塩水 (大塚製薬株式会社製)(比較試験例 5-1)又はラベン ダー精油含有溶液 (ラベンダー精油 1重量%、界面活性剤 5重量%、残部水)(比較 試験例 5-2)を用いて、上記と同様に試験を行った。  Three subjects with hay fever with nasal discomfort were selected as subjects. Three subjects were administered by allowing 20 g of the lavender steam distilled water obtained in Example 1 to flow into the nasal cavity and then draining it. After administration, subjects were immediately put to bed and evaluated how lavender steam-distilled water had an effect on sleep! // (Study Example 5). The evaluation was performed according to the following evaluation criteria for (1) falling asleep, (2) depth of sleep, (3) awakening during sleep, and (4) awakening. For comparison, instead of lavender steam-distilled water, physiological saline (manufactured by Otsuka Pharmaceutical Co., Ltd.) (Comparative Test Example 5-1) or lavender essential oil-containing solution (1% by weight of lavender essential oil, surfactant 5) The test was conducted in the same manner as described above using (weight%, balance water) (Comparative Test Example 5-2).
<評価基準 >  <Evaluation criteria>
A: V、つもに比べて良好である  A: V, better than Tsum
B: V、つもに比べて変わりがな!ヽ  B: V, no change compared to Tsumo!
C :いつもに比べて悪い。 [0039] 得られた結果を表 6に示す。この結果、本発明の鼻腔用組成物には、優れた安眠 誘発効果があること確認された。この結果から、本発明の鼻腔用組成物は、鼻腔内 に長時間留まることが可能であるため、睡眠中にわたって鼻の不快症状を改善し、更 に本発明品の香気成分によって睡眠中の問題を改善していることが示唆された。 C: Bad compared to usual. [0039] Table 6 shows the obtained results. As a result, it was confirmed that the composition for nasal cavity of the present invention has an excellent sleep inducing effect. From this result, since the composition for nasal cavity of the present invention can stay in the nasal cavity for a long time, it improves nasal discomfort during sleep, and furthermore, the problem of sleeping due to the fragrance component of the present invention. It was suggested that
[0040] [表 6]  [0040] [Table 6]
Figure imgf000011_0001
Figure imgf000011_0001
表中の数は、 人数を示す。 参者例 組成分析  The numbers in the table indicate the number of people. Participant example Composition analysis
実施例 1で得られたラベンダーの水蒸気蒸留水、及びラベンダー精油について、 ガスクロマトグラフィーにより成分分析を行った。分析対象のラベンダー精油には、実 施例 1において、水蒸気蒸留により製された蒸留液力も回収した油相を用いた。分析 には、実施例 1で得られたラベンダーの水蒸気蒸留水 47. 5gにへキサン 2. 5gを混 合したもの、及び上記ラベンダー精油をメタノールで 1重量%に希釈したものを試料 として使用した。分析条件は、以下の通りである。  The lavender steam distilled water and lavender essential oil obtained in Example 1 were subjected to component analysis by gas chromatography. As the lavender essential oil to be analyzed, the oil phase in which the distillate power produced by steam distillation was recovered in Example 1 was used. For the analysis, 47.5 g of lavender steam distilled water obtained in Example 1 was mixed with 2.5 g of hexane, and the lavender essential oil diluted to 1% by weight with methanol was used as samples. . The analysis conditions are as follows.
<分析条件 >  <Analysis conditions>
ガスクロマトグラフ装置  Gas chromatograph
Hewlett Packard 社製  Hewlett Packard
HP6890シリーズ  HP6890 series
DB- 5MS DB-5MS
長さ 30m  Length 30m
内径 0. 25mm  ID 0.25 mm
膜厚 0. 25 /x m  Film thickness 0.25 / x m
オーブン 初期温度 50°C7分 oven Initial temperature 50 ° C 7 minutes
毎分 5°Cで 100°Cまで昇温  Heated up to 100 ° C at 5 ° C per minute
毎分 20°Cで 250°Cまで昇温  Heated up to 250 ° C at 20 ° C per minute
250。C定温 10. 5分  250. C constant temperature 10.5 min
分析合計時間 45分  Total analysis time 45 minutes
注入口 Inlet
温度 250°C  Temperature 250 ° C
スプリット比 10: 1  Split ratio 10: 1
総流量 9. 8mlZ分  Total flow rate 9.8mlZ min
キャリアガス 超高純度ヘリウム  Carrier gas Ultra high purity helium
試料 ft人量 Sample ft
2 μ \  2 μ \
FID (水素炎イオン化)検出器。 FID (hydrogen flame ionization) detector.
ラベンダーの水蒸気蒸留水について得られたクロマトグラフを図 1に、またラベンダ 一精油について得られたクロマトグラフを図 2に示す。図 1と図 2ではピークパターン が相違しており、ラベンダーの水蒸気蒸留水とラベンダー精油とでは、その組成を異 にするものであることが確認された。  Figure 1 shows the chromatograph obtained for lavender steam distilled water, and Figure 2 shows the chromatograph obtained for Lavender mono essential oil. The peak patterns are different between Fig. 1 and Fig. 2, and it was confirmed that the composition of lavender steam distilled water and lavender essential oil differ.

Claims

請求の範囲 The scope of the claims
[1] ラベンダーの水蒸気蒸留水を含有する、鼻腔用組成物。  [1] A composition for nasal cavity containing lavender steam distilled water.
[2] ラベンダーの水蒸気蒸留水力 ラベンダーの地上部又は全草力 得られるものであ る、請求項 1に記載の鼻腔用組成物。  [2] Steam-distilled hydropower of lavender The nasal composition according to claim 1, wherein the above-ground or whole-plant power of lavender is obtained.
[3] ラベンダーが、おかむらさき又はその改良品種である、請求項 1又は 2に記載の鼻腔 用組成物。 [3] The composition for nasal cavity according to claim 1 or 2, wherein the lavender is Okamurasaki or an improved variety thereof.
PCT/JP2005/006391 2004-09-30 2005-03-31 Composition for nasal cavity WO2006006283A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004289197A JP2006104076A (en) 2004-09-30 2004-09-30 Composition for nasal foramen
JP2004-289197 2004-09-30

Publications (1)

Publication Number Publication Date
WO2006006283A1 true WO2006006283A1 (en) 2006-01-19

Family

ID=35783644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/006391 WO2006006283A1 (en) 2004-09-30 2005-03-31 Composition for nasal cavity

Country Status (2)

Country Link
JP (1) JP2006104076A (en)
WO (1) WO2006006283A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009292735A (en) * 2008-06-02 2009-12-17 Kinjirushi Kk Allergic disease-suppressing composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01185267A (en) * 1988-01-19 1989-07-24 Geran Kaihatsu Kenkyusho:Kk New inhalator
JPH06165619A (en) * 1992-09-16 1994-06-14 Hokkaido Nogyo Shikenjo Method for retaining freshness of cut flower of lavender
JP2000212589A (en) * 1999-01-20 2000-08-02 Cosmo Ace:Kk Plant essential oil-containing aqueous solution and its production
JP2002502391A (en) * 1997-05-30 2002-01-22 ザ、プロクター、エンド、ギャンブル、カンパニー Disinfecting composition and surface disinfecting method
JP2003192568A (en) * 2001-12-27 2003-07-09 Nonogawa Shoji Kk Fragrant cosmetic composition
JP2004238299A (en) * 2003-02-04 2004-08-26 Ichimaru Pharcos Co Ltd Cosmetic composition containing steam-distilled water originating from plant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0477433A (en) * 1990-07-18 1992-03-11 Zenkoku Nogyo Kyodo Kumiai Rengokai Fight-preventing and stress-relaxing agent for pig
JPH0884949A (en) * 1994-09-16 1996-04-02 Koki Bussan Kk Liquid composition for atomization of ultrasonic atomizer
US5706800A (en) * 1997-01-29 1998-01-13 Cronk; Peter J. Medicated nasal dilator
JP2003327992A (en) * 2002-05-08 2003-11-19 Yoshiko Yamamoto Essential oil composition and patch

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01185267A (en) * 1988-01-19 1989-07-24 Geran Kaihatsu Kenkyusho:Kk New inhalator
JPH06165619A (en) * 1992-09-16 1994-06-14 Hokkaido Nogyo Shikenjo Method for retaining freshness of cut flower of lavender
JP2002502391A (en) * 1997-05-30 2002-01-22 ザ、プロクター、エンド、ギャンブル、カンパニー Disinfecting composition and surface disinfecting method
JP2000212589A (en) * 1999-01-20 2000-08-02 Cosmo Ace:Kk Plant essential oil-containing aqueous solution and its production
JP2003192568A (en) * 2001-12-27 2003-07-09 Nonogawa Shoji Kk Fragrant cosmetic composition
JP2004238299A (en) * 2003-02-04 2004-08-26 Ichimaru Pharcos Co Ltd Cosmetic composition containing steam-distilled water originating from plant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUCHBAUER G ET AL: "Aromatherapy: evidence for sedative effects of the essential oil of lavender after inhalation.", J OF BIOSCIENCES., vol. 46, no. 11-12, 1991, pages 1067 - 1072, XP002989855 *
ISHIDUKA Y E TAL: "Geraniol oyobi Citronerol Shiyo Chewing Gum no Sugi Kafunsho ni Taisuru Hyoka.", THE FOOD INDUSRY., vol. 38, no. 8, 1995, pages 58 - 62, XP002996100 *
PLOTTO A ET AL: "Aroma quality of lavender water: a comparative study.", PERFUMER & FLAVORIST., vol. 26, no. 3, 2001, pages 44 - 64, XP002989847 *

Also Published As

Publication number Publication date
JP2006104076A (en) 2006-04-20

Similar Documents

Publication Publication Date Title
US20100303935A1 (en) Medicinal Composition
US20220218595A1 (en) Method of using soothing cream including maca root extract as an active ingredient
US20040101577A1 (en) Composition for treating acne vulgaris and fabrication method
US20220110993A1 (en) Compositions for treatment of jaw pain, temporomandibular joint and muscle disorder and bruxism
CN108853356B (en) Male delayed spray and preparation method thereof
KR20190122306A (en) A compound for preventing hair loss and promoting hair growth
WO2006006283A1 (en) Composition for nasal cavity
KR100465971B1 (en) Helichrysum oil possessing anti-inflammatory effect and cosmetic composition containing thereof
KR20030040514A (en) Eye drops
US7666450B2 (en) Herbal compositions for the regression of chronic inflammatory skin disorders
CN108451799A (en) A kind of hand cleanser and preparation method thereof
KR101127393B1 (en) Composition for preventing or alleviating atopic dermatitis, and process for preparing the same
WO2011054310A1 (en) Tieguanyin healthcare tea
JP3451519B2 (en) Chewing gum using menthol and cineole containing fragrance
JP6181243B1 (en) Method for producing external preparation for skin and external preparation for skin produced by the production method
CN111481597B (en) Female herbal bacteriostatic care solution and preparation method thereof
CN111035684A (en) Ozone oil compound rhinitis gel and preparation method thereof
KR102211169B1 (en) Nontoxic natural liquid soap composition with anti-pimples, follicles and atopic dermatitis prevention and mitigation effects and non-toxic natural liquid soap with atopic dermatitis prevention and mitigation effects manufactured using it
KR20040065498A (en) Allergic dermatitis and skin itching relieving composition containing natural herb extract
KR102319379B1 (en) Composition comprising banana leaf extract for antioxidant, antidepressant and antistress
KR102537835B1 (en) Composition comprising fraxinus rhynchophylla extract for antidepressant and antistress
TWI728339B (en) Composition containing grapefruit seed and brown rice extract
KR102319382B1 (en) For antioxidant, antidepressant and antistress compositions comprising boswellia
WO2006006280A1 (en) Skin astringent
JP2009091279A (en) Mugwort essential oil external preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 05727521

Country of ref document: EP

Kind code of ref document: A1